



LET YOUR PATIENTS  
**WAKE UP TO NEW POSSIBILITIES**

# **RYBELSUS**<sup>®</sup>

semaglutide tablets

A GAME CHANGER. A LIFE CHANGER

THE WORLD'S FIRST AND ONLY  
**ORAL GLP-1 RA<sup>1</sup>**



**AVAILABLE  
NOW**



**GLP-1 RA:** Glucagon-like peptide-1 receptor agonist.  
**Reference:** 1. RYBELSUS<sup>®</sup> [package insert]. Plainsboro, NJ: Novo Nordisk Inc; April 2021.  
Rybelsus is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  
\* As monotherapy when metformin is considered inappropriate due to intolerance or contraindications;  
\* In combination with other medicinal products for the treatment of diabetes.

For healthcare professionals only.  
For full prescribing information, refer to package insert.

Rybelsus<sup>®</sup> and The Apis bull logo are register trademarks of Novo Nordisk A/S. Please refer latest summary of product characteristics for more details. For the use of a registered medical practitioner or a hospital or a laboratory only.  
To get information on the updated package insert please contact +91 80 4030 3200 or write to us at [INAgree@novonordisk.com](mailto:INAgree@novonordisk.com)

IN22RYB00046